Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010

ProUroCare signs agreement with Seaside 88 LP

ProUroCare Medical Inc., a provider of proprietary imaging products, today announced the signing of an agreement for $3.125 million in equity financing with Seaside 88 LP of Juno Beach, Fla.

29 Sep 2010

Escalon Medical reports 0.2% increase in product revenue for fiscal year 2010

Escalon Medical Corp. today announced results for its fiscal year ended June 30, 2010. Consolidated product revenue from continued operations for fiscal 2010 increased approximately 0.2% to $30,657,000, compared with $30,600,000 in the prior fiscal year.

29 Sep 2010

IsoRay reports increase revenue for 2010 fiscal year

IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash.

28 Sep 2010

AP poll: Americans who think health law should do more outnumber those who think government should stay out of it

As Republicans seek to use the health law as a major talking point to help them win more seats in Congress, a "new AP poll finds that Americans who think the law should have done more outnumber those who think the government should stay out of health care by 2-to-1." The poll found four in 10 adults think the law didn't go far enough to change the system "regardless of whether they support the law, oppose it or remain neutral. On the other side, about one in five say they oppose the law because they think the federal government should not be involved in health care at all."

28 Sep 2010

Stirling Products’ drug delivery technology interests big ‘pharma’

Healthcare group, Stirling Products Limited (ASX:STI) has advised that following the recent TeleMedCare e-health acquisition and the conditional addition of the recently announced pathology business (subject to due diligence completion and shareholder approval), the Company is now in process of its strategised business integration.

26 Sep 2010

Gore completes enrollment in study of VIABAHN Endoprosthesis with Heparin Bioactive Surface

W. L. Gore & Associates (Gore) reported the complete enrollment in a post-market approval study designed to better characterize the performance of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in treating peripheral vascular disease (PVD) of the superficial femoral artery (SFA). The 11 participating sites enrolled a total of 120 patients in the Gore VIPER (GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface for SuPERficial Femoral Artery Endoluminal Bypass) Study since initiation.

24 Sep 2010

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.

24 Sep 2010

World Heart Federation calls on employers and employees to take responsibility for workplace wellness

Despite the vast majority (91%) of workers believing that it is their employer's responsibility to create a healthy working environment, nearly a third (32%) of employees feels their workplace actually hinders their ability to lead a healthy lifestyle, according to new independent research commissioned by the World Heart Federation and conducted by Opinion Health.

24 Sep 2010

Sokolove Law to recognize Mesothelioma Awareness Day on September 26

On September 26, 2010, Sokolove Law will recognize Mesothelioma Awareness Day, which was inaugurated five years ago by the Mesothelioma Applied Research Foundation (MARF) to bring attention to this deadly, incurable and often overlooked cancer.

24 Sep 2010

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.

24 Sep 2010

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

NeoStem, Inc. an international biopharmaceutical company with operations in the U.S. and China and Progenitor Cell Therapy, LLC a privately held cell therapy company that serves the cell therapy industry from licensed, state-of-the art cell therapy manufacturing facilities in New Jersey and California today jointly announced the signing of a definitive merger agreement whereby NeoStem will acquire Progenitor Cell Therapy.

24 Sep 2010

FDA approves Bionovo's CMC plan for Menerba drug candidate

Bionovo, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba, in a Type "B" or "End of Phase 2" meeting.

24 Sep 2010

Surefil emerges from Chapter 11 protection with Federal Court approval

Surefil, a contract manufacturer of liquid-fill products for the personal care, home care, oral care, medical industries, and energy drinks, emerged from Chapter 11 protection with Federal Court approval on September 15, 2010.

23 Sep 2010

MDS Nordion, Isotope enter framework agreement

MDS Nordion, a leading provider of products and services to the global health science market, today announced it has entered into a framework agreement with The Open Joint Stock Company "Isotope" the authorized subsidiary of Rosatom State Corporation, to explore and define areas of collaboration in the field of supply, marketing and sale of isotopes produced in Russia.

23 Sep 2010

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Scarab Genomics, a pioneer in the world of E. coli genomics and production strains, and Lonza, a world leader in biopharmaceutical development and production, announced today the companies have entered into a preferred marketing and sales agreement for Scarab Genomics' Clean Genome E. coli. Financial details of the contract were not disclosed.

23 Sep 2010

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

W. L. Gore & Associates announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.

23 Sep 2010

DuPont and Royal DSM enter joint venture for advanced surgical biomedical materials

DuPont and Royal DSM N.V. announce an agreement to form a joint venture to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval. The joint venture will be named Actamax Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will each share a 50 percent interest.

23 Sep 2010

Manufacturing News and Research

Further Reading

CAP cells produce high virus titers upon influenza strain infection

ProUroCare signs agreement with Seaside 88 LP

Escalon Medical reports 0.2% increase in product revenue for fiscal year 2010

IsoRay reports increase revenue for 2010 fiscal year

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

AP poll: Americans who think health law should do more outnumber those who think government should stay out of it

Stirling Products’ drug delivery technology interests big ‘pharma’

Gore completes enrollment in study of VIABAHN Endoprosthesis with Heparin Bioactive Surface

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

World Heart Federation calls on employers and employees to take responsibility for workplace wellness

Sokolove Law to recognize Mesothelioma Awareness Day on September 26

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

FDA approves Bionovo's CMC plan for Menerba drug candidate

Surefil emerges from Chapter 11 protection with Federal Court approval

MDS Nordion, Isotope enter framework agreement

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

DuPont and Royal DSM enter joint venture for advanced surgical biomedical materials

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy